Cyclin-dependent kinase inhibitor p27(Kip1) expression and interaction with other cell cycle-associated proteins in mammary carcinoma

Journal of Pathology

Volumn 187, Issue 2, 1999, Pages 200-206

  Gillett, Cheryl E ^a   Smith, Paul ^a   Peters, Gordon ^b   Lu, Xin ^c   Barnes, Diana M ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Breast cancer; Cyclin D1; p27; Prognosis; Retinoblastoma protein

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P27; RETINOBLASTOMA PROTEIN;

ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CELL CYCLE; CELL PROLIFERATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

BREAST NEOPLASMS; CELL CYCLE PROTEINS; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; DISEASE-FREE SURVIVAL; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PROGNOSIS; RETINOBLASTOMA PROTEIN; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 0032902972     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199901)187:2<200::AID-PATH228>3.0.CO;2-M     Document Type: Article

References (39)

1. Pardee AB. G1 events and regulation of cell proliferation. Science 1989; 246: 603-608.
2. Weinberg RA. The molecular basis of carcinogenesis: understanding the cell cycle clock. Cytokines Mol Ther 1996; 2: 105-110.
3. Herwig S, Strauss M. The retinoblastoma protein: a master regulator of cell cycle, differentiation and apoptosis. Eur J Biochem 1997; 246: 581-601.
4. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995; 9: 1149-1163.
5. Morgan DO. Principles of Cdk regulation. Nature 1995; 374: 131-134.
6. Mann DJ, Higgins T, Jones T, Rozengert E. Differential control of cyclins D1 and D3 and the Cdk inhibitor p27Kipl by diverse signalling pathways in Swiss 3T3 cells. Oncogene 1997; 14: 1759-1766.
7. Peters G. Stifled by inhibitions. Nature 1994; 371: 204-205.
8. Biggs JR, Kraft AS. Inhibitors of cyclin dependent kinase and cancer. J Mol Med 1995; 73: 509-514.
9. Parwaresch R, Rudolph P. The cell cycle - theory and application to cancer. Onkologie 1996; 19: 464-472.
10. Soos TJ, Kiyokawa H, Yan JS, et al. Formation of p27-CDK complexes during the human mitotic cell cycle. Cell Growth Diff 1996; 7: 135-146.
11. LaBaer J, Garrett M, Stevenson LF, et al. New functional activities for the p21 family of CDK inhibitors. Genes Dev 1997; 11: 847-862.
12. Pagano M, Tam SW, Theodoras AM, et al. Role of the ubiquitin pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995; 269: 682-685.
13. Sgambato A, Doki Y, Schieren I, Weinstein IB. Effects of cyclin E overexpression on cell growth and response to transforming growth factor beta depend on cell context and p27Kipl expression. Cell Growth Diff 1997; 8: 393-405.
14. Han EK, Begemann M, Sgambato A, et al. Increased expression of cyclin D1 in a murine mammary epithelial cell line induces p27Kipl, inhibits growth and enhances apoptosis. Cell Growth Diff 1996; 7: 699-710.
15. Aagaard L, Lukas J, Bartkova J, Kjerulff A-A, Strauss M, Bartek J. Aberrations of p16Ink4 and retinoblastoma tumour-suppressor genes occur in distinct sub-sets of human cancer cell lines. Int J Cancer 1995; 61: 115-120.
16. Renisdottir I, Polyak K, Iavarone A, Massague J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev 1995; 9: 1831-1845.
17. Renisdottir I, Massague J. The subcellular locations of p15(Ink4b) and p27 (Kipl) coordinate their inhibitory actions with Cdk4 and Cdk2. Genes Dev 1997; 11: 492-503.
18. Catzavelos B, Bhattacharya N, Ung YC. Decreased levels of the cell-cycle inhibitor p27 protein: prognostic implications in primary breast cancer. Nature Med 1996; 3: 227-230.
19. Porter PL, Malone KE, Heagerty PJ, et al. Expression of cell-cycle regulators p27Kipl and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Med 1997; 3: 222-225.
20. 1a,b) invasive breast carcinomas. Cancer Res 1997; 57: 1259-1263.
21. Gillett C, Smith P, Gregory W, et al. Cyclin D1 and prognosis in human breast cancer. Int J Cancer (Pred Oncol) 1996; 69: 92-99.
22. Dublin EA, Patel NK, Gillett CE, Smith P, Peters G, Barnes DM. Retinoblastoma and p16 proteins in mammary carcinoma: their relationship to cyclin D1 and histopathological parameters. Int J Cancer (Pred Oncol) 1998; 79: 71-75.
23. Fredersdorf S, Burns J, Milne AM. High level expression of p27 and cyclin D1 in some proliferating tumour cells: inverse correlation with the degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 1997; 94: 6380-6385.
24. Camplejohn RS. Flow cytometry in clinical pathology. In: Herrington CS, McGree JOD, eds. Diagnostic Molecular Pathology: A Practical Approach, Oxford: I.R.L. Press, 1992; 238-259.
25. World Health Organisation, Geneva, Switzerland. Histological typing of breast tumors. Tumori 1982; 68: 181-198.
26. Elston CW, Gresham GAS, Rao GS, et al. The Cancer Research Campaign (Kings/Cambridge) trial for early breast cancer: clinicopathological aspects. Br J Cancer 1982; 45: 655-669.
27. King RJB, Redgrave S, Hayward JL, Millis RR, Rubens RD. The measurement of receptors for oestradiol and progesterone in human breast tumours. In: King RJ, ed. Steroid Receptor Assays in Breast Tumors: Methodological and Clinical Aspects. Cardiff: Alpha-Omega, 1979; 55-73.
28. Golding H, Pinder S, Cannon P, et al. A new method for the assessment of oestrogen receptor status on routine formalin fixed tissue samples. Hum Pathol 1995; 26: 291-294.
29. Andersen J, Thorpe SM, King WJ, et al. The prognostic value of immunohistochemical estrogen receptor analysis in paraffin-embedded and frozen sections versus that of steroid-binding assays. Eur J Cancer 1990; 26: 442-449.
30. Barnes DM, Harris WH, Smith P, Millis RR. Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer 1996; 74: 1445-1451.
31. Peto R, Pike MC, Armitage P, et al. Design and analysis of clinical trials requiring prolonged observation of each patient: II analysis and examples. Br J Cancer 1970; 35: 1-39.
32. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34B: 187-220.
33. Kipl for restriction point control of the fibroblast cell cycle. Science 1996; 272: 877-880.
34. 0 state) in fibroblasts. J Biol Chem 1996; 271: 18337-18341.
35. Juan G, Gong J, Traganos F, Darzynkiewicz Z. Unscheduled expression of cyclins D1 and D3 in human tumour cell lines. Cell Prolif 1996; 29: 259-266.
36. Musgrove EA, Hamilton JA, Lee CSL, Sweeny KJE, Watts CKW, Sutherland RL. Growth factor, steroid and steroid agonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell progression. Mol Cell Biol 1993; 13: 3577-3587.
37. Nielson NH, Emdin SO, Cajander J, Landberg G. Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein. Oncogene 1997; 14: 295-304.
38. Neuman E, Ladha MH, Lin N, et al. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of Cdk4. Mol Cell Biol 1997; 17: 5338-5347.
39. Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernhards R, Michalides RJAM. CDK-independent activation of estrogen receptor by cyclin D1. Cell 1997; 88: 405-415.